Niagen Bioscience, Inc. (NAGE) Tops Q4 EPS by 3c, offers outlook

Niagen Bioscience, Inc. (NASDAQ: NAGE) reported Q4 EPS of $0.05, $0.03 better than the analyst estimate of $0.02. Revenue for the quarter came in at $33.8 million versus the consensus estimate of $31.7 million.

2026 Outlook

Net sales: Increasing between 10-15% year-over-year excluding 2025 revenue attributable to the Analytical Reference Standards and Services segment, driven primarily by e-commerce business and new strategic partnerships.
Gross margin: Slight improvement year-over-year, driven by improvements in inventory cost and product mix.
Sales & marketing: Increase in absolute dollars, but stable as a percentage of sales, driven by optimized investments to drive customer acquisition and support the launch of new verticals.
Research & development: Increase in absolute dollars, driven by investment into pharmaceutical development and continued external research initiatives.
General & administrative: $4.0 million to $5.0 million increase driven by infrastructure investments and legal expenses to support the growth of existing business and new market launches, as well as increased share-based compensation expense with the absence of credit loss recovery.

For earnings history and earnings-related data on Niagen Bioscience, Inc. (NAGE) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Horizon Bancorp names two independent directors to its board
• Klarna shares tumble on weak full-year revenue guidance